product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Phospho-Bad (Ser136) (D25H8) Rabbit mAb
catalog :
4366P
quantity :
40 ul
price :
123 USD
clonality :
monoclonal
host :
rabbit
antigen modification :
phosphorylated
reactivity :
human, mouse, rat
application :
western blot, immunoprecipitation
more info or order :
Cell Signaling Technology product webpage
citations: 7
Published Application/Species/DilutionReference
  • western blot; human; fig 4
Luey B, May F. Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway. Mol Cancer. 2016;15:8 pubmed publisher
  • western blot; rat; 1:1000; fig 4
Zhang H, Xiong Z, Wang J, Zhang S, Lei L, Yang L, et al. Glucagon‑like peptide‑1 protects cardiomyocytes from advanced oxidation protein product‑induced apoptosis via the PI3K/Akt/Bad signaling pathway. Mol Med Rep. 2016;13:1593-601 pubmed publisher
  • western blot; mouse; 1:1000; tbl 1
Guillot F, Kemppainen S, Lavasseur G, Miettinen P, Laroche S, Tanila H, et al. Brain-Specific Basal and Novelty-Induced Alternations in PI3K-Akt and MAPK/ERK Signaling in a Middle-Aged AβPP/PS1 Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2016;51:1157-73 pubmed publisher
  • western blot; human; fig 2
Moody S, Schinzel A, Singh S, Izzo F, Strickland M, Luo L, et al. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene. 2015;34:2061-71 pubmed publisher
  • western blot; mouse; 1:1000; fig 4
Wu C, Hung T, Chen C, Ke C, Lee C, Wang P, et al. Post-injury treatment with 7,8-dihydroxyflavone, a TrkB receptor agonist, protects against experimental traumatic brain injury via PI3K/Akt signaling. PLoS ONE. 2014;9:e113397 pubmed publisher
  • western blot; human; fig 1
Riaz A, Zeller K, Johansson S. Receptor-specific mechanisms regulate phosphorylation of AKT at Ser473: role of RICTOR in β1 integrin-mediated cell survival. PLoS ONE. 2012;7:e32081 pubmed publisher
Carlino M, Fung C, Shahheydari H, Todd J, Boyd S, Irvine M, et al. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. Clin Cancer Res. 2015;21:98-105 pubmed publisher
product information
SKU :
4366P
Product-Name :
Phospho-Bad (Ser136) (D25H8) Rabbit mAb
Size :
40 ul
Price-(USD) :
123 USD
Species-x-Reactivity :
H, M, Mk, (R)
Applications :
Immunoprecipitation
Product-Category :
Apoptosis
Shipping-Temp :
COLD
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
23
Host :
Rabbit
Target :
Bad (Ser99) phosphate
Primary-Protein :
BAD
Alt-Names :
BAD,BBC2,BBC6,BCL-X/BCL-2 binding protein,BCL2-antagonist of cell death protein,BCL2-associated agonist of cell death,BCL2-binding component 6,BCL2-binding protein,BCL2L8,Bcl-2-binding component 6,Bcl-2-like protein 8,Bcl-XL/Bcl-2-associated death promoter,Bcl2 antagonist of cell death,Bcl2-L-8
more info or order :
Cell Signaling Technology product webpage
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.